Clinical Scorecard: Wegovy HD Secures FDA Approval

At a Glance

Key Highlights

• FDA approved semaglutide 7.2 mg (Wegovy HD) based on phase 3 STEP UP trials demonstrating significant weight loss
• Mean weight loss of 20.7% in adults with obesity and 14.1% in adults with obesity and type 2 diabetes over 72 weeks
• Safety and tolerability consistent with previous semaglutide studies; multiple formulations approved including injectable and oral

Guideline-Based Recommendations

Diagnosis

• Identify adults with obesity or overweight, including those with type 2 diabetes, as candidates for semaglutide therapy

Management

• Administer semaglutide 7.2 mg once weekly via injection alongside lifestyle interventions
• Consider semaglutide for long-term weight reduction and maintenance
• Use in adults and pediatric patients aged 12 years and older as indicated

Monitoring & Follow-up

• Monitor weight loss progress and tolerability during treatment
• Assess for adverse events consistent with semaglutide safety profile

Risks

• Potential adverse effects consistent with prior semaglutide studies; monitor accordingly

Patient & Prescribing Data

Approximately 1,400 adults with obesity and 500 adults with obesity and type 2 diabetes in clinical trials

Significant mean weight loss achieved (20.7% and 14.1%, respectively) with a favorable safety and tolerability profile

Clinical Best Practices

• Incorporate semaglutide 7.2 mg as part of a comprehensive obesity management plan including lifestyle modification
• Educate patients on the importance of adherence to once-weekly dosing
• Monitor for efficacy and adverse effects regularly
• Consider semaglutide for patients with obesity-related comorbidities such as type 2 diabetes and cardiovascular disease

References

• Novo Nordisk Press Release on Wegovy HD FDA Approval